New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The shot, named mFlusiva, is intended for adults age 50 or older.

Health Secretary Robert F. Kennedy Jr pulled $500 million in funding for mRNA vaccine development last year - the medical community said the U.S. would pay the price in dollars and lives

The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna. The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already ha

The shot, named mFlusiva, is intended for adults age 50 or older. Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review  wsj.com

The mFlusiva vaccine for older people is the first made with the mRNA platform key to ending the coronavirus pandemic The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufact

The shot, made by Moderna, will be available for this year's upcoming flu season.

The U.S. Food and Drug Administration has approved a new mRNA-based seasonal flu vaccine for people 50 and older, Moderna said this week.

In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more.

The flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab

The Food and Drug Administration on Wednesday approved the first mRNA-based influenza vaccine, marking a milestone for the technology, which was first widely used during the COVID-19 pandemic. The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of se

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine  AP News

The U.S. Food and Drug Administration has approved Moderna’s flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu.

A younger and higher-educated base were pivotal to Abdul El Sayed’s Senate Primary win, an analysis shows.

The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna.  The agency approved the shot for two separate age groups; people age 50 to 64, and for 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the effec

After refusing to even review it, the FDA has approved Moderna's mRNA seasonal flu vaccine.

FDA Approves First mRNA Flu Vaccine For Older Adults  Forbes

The Food and Drug Administration approved Moderna's mRNA seasonal flu vaccine on Wednesday.

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.

The shot, mFlusiva, was given a ​traditional approval for adults aged 50 to 64.

FDA approves first mRNA-based flu vaccine  CNN

The agency had initially refused to even review the application but reversed course after a public outcry.

US FDA approves first mRNA flu shot from Moderna  Reuters